PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Apremilast - Psoriatic arthritis
PAD Profile : Apremilast - Psoriatic arthritis
Keywords :
Biologic, NICE, immunosuppressant, phosphodiesterase type-4 inhibitor, PDE4 inhibitor, DMARD, bDmard, Disease modulating, Reumatology, biosimilar
Brand Names Include :
Otezla
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Adalimumab
- Ciclosporin
- Etanercept
- Golimumab
- Infliximab
- Sulfasalazine
- Ustekinumab (Psoriasis)
- Certolizumab pegol
- Secukinumab
- Ixekizumab
- Tofacitinib
- Methotrexate
- Guselkumab (Psoriasis)
- Upadacitinib
- Risankizumab
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Apremilast as a treatment option for treating active psoriatic arthritis in line with NICE TA433 (22nd February 2017).
Apremilast is a payment by results excluded drug which will be considered RED on the traffic light system.
Please see the current psoriatic arthritis treatment pathway below.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs